News & Events - Page 3 of 3 - MitoRx

- Publication
- Posted 12 May, 2025
The novel small molecule Myo4 normalises glycemic control, reduces weight/fat mass and prevents semaglutide-induced muscle remodelling in the murine diet-induced obesity model
Read More
- Press Release
- Posted 1 May, 2025
MitoRx Therapeutics appoints Xavier Jacq as CSO
Read More
- Press Release
- Posted 9 January, 2025
MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director
Read More
- Press Release
- Posted 10 October, 2024
MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity
Read More
- Press Release
- Posted 3 October, 2024
MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme
Read More
- Press Release
- Posted 7 March, 2024
MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts
Read More
- Press Release
- Posted 13 December, 2023
MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
Read More
- Press Release
- Posted 7 March, 2023
MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.
Read More
- Press Release
- Posted 25 April, 2022
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
Read More